4A1 Stock Overview
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Cereno Scientific AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.36 |
52 Week High | kr0.47 |
52 Week Low | kr0.025 |
Beta | 0.052 |
1 Month Change | 13.66% |
3 Month Change | 8.09% |
1 Year Change | 1,063.11% |
3 Year Change | 10.25% |
5 Year Change | n/a |
Change since IPO | 26.55% |
Recent News & Updates
Recent updates
Shareholder Returns
4A1 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 6.8% | 0.7% | -0.8% |
1Y | 1,063.1% | -23.7% | 3.2% |
Return vs Industry: 4A1 exceeded the German Biotechs industry which returned -23.9% over the past year.
Return vs Market: 4A1 exceeded the German Market which returned 3.2% over the past year.
Price Volatility
4A1 volatility | |
---|---|
4A1 Average Weekly Movement | 7.8% |
Biotechs Industry Average Movement | 5.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.6% |
10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 4A1 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4A1's weekly volatility has decreased from 20% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 5 | Sten Sorensen | www.cerenoscientific.com |
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases.
Cereno Scientific AB (publ) Fundamentals Summary
4A1 fundamental statistics | |
---|---|
Market cap | €105.09m |
Earnings (TTM) | -€4.21m |
Revenue (TTM) | €4.32m |
24.3x
P/S Ratio-24.9x
P/E RatioIs 4A1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4A1 income statement (TTM) | |
---|---|
Revenue | kr49.28m |
Cost of Revenue | kr0 |
Gross Profit | kr49.28m |
Other Expenses | kr97.38m |
Earnings | -kr48.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 29, 2024
Earnings per share (EPS) | -0.17 |
Gross Margin | 100.00% |
Net Profit Margin | -97.62% |
Debt/Equity Ratio | 21.0% |
How did 4A1 perform over the long term?
See historical performance and comparison